Rare Tumour Working Group. Active Trials. GOG 187 Phase 2 paclitaxel as 2 nd line therapy for ovarian stromal tumours-almost complete GOG239-Phase 2 AZD6244(MEK inhibitor) in recurrent low grade serous cancers recruiting well –target 50
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Phase 2 study of Aromatase inhibitors in women with potentially hormone Responsive recurrent/metastatic Gynaecological Neoplasms
Difficult to investigate the role of hormonal therapy, for uncommon subtypes of gynaecological cancers, as there is a disincentive to submit ethics applications and open studies where the expectation is that they might only recruit 1 or 2 patients a year.
The aim of the study is to evaluate the activity of anastrozole in women with recurrent or metastatic potentially hormone responsive gynaecological cancers
- epithelial ovarian cancer,
-sex cord stromal tumours of the ovary,
- endometrial sarcomas and miscellaneous sarcomas.